IL229032B - Microrna compounds and methods for modulating mir-21 activity - Google Patents

Microrna compounds and methods for modulating mir-21 activity

Info

Publication number
IL229032B
IL229032B IL229032A IL22903213A IL229032B IL 229032 B IL229032 B IL 229032B IL 229032 A IL229032 A IL 229032A IL 22903213 A IL22903213 A IL 22903213A IL 229032 B IL229032 B IL 229032B
Authority
IL
Israel
Prior art keywords
mir
methods
micro rna
modulate activity
rna compounds
Prior art date
Application number
IL229032A
Other languages
English (en)
Hebrew (he)
Other versions
IL229032A0 (en
Original Assignee
Sanofi Sa
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Regulus Therapeutics Inc filed Critical Sanofi Sa
Publication of IL229032A0 publication Critical patent/IL229032A0/en
Publication of IL229032B publication Critical patent/IL229032B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
IL229032A 2011-04-25 2013-10-23 Microrna compounds and methods for modulating mir-21 activity IL229032B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US201161565779P 2011-12-01 2011-12-01
PCT/US2012/034880 WO2012148952A1 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Publications (2)

Publication Number Publication Date
IL229032A0 IL229032A0 (en) 2013-12-31
IL229032B true IL229032B (en) 2021-01-31

Family

ID=46025979

Family Applications (3)

Application Number Title Priority Date Filing Date
IL229032A IL229032B (en) 2011-04-25 2013-10-23 Microrna compounds and methods for modulating mir-21 activity
IL266529A IL266529A (en) 2011-04-25 2019-05-08 MicroRNA compounds and methods to modulate mir-21 activity
IL273381A IL273381A (en) 2011-04-25 2020-03-18 MicroRNA compounds and methods to modulate mir-21 activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL266529A IL266529A (en) 2011-04-25 2019-05-08 MicroRNA compounds and methods to modulate mir-21 activity
IL273381A IL273381A (en) 2011-04-25 2020-03-18 MicroRNA compounds and methods to modulate mir-21 activity

Country Status (30)

Country Link
US (7) US20120270928A1 (cg-RX-API-DMAC7.html)
EP (3) EP2702155B9 (cg-RX-API-DMAC7.html)
JP (2) JP6320292B2 (cg-RX-API-DMAC7.html)
KR (2) KR102055172B1 (cg-RX-API-DMAC7.html)
CN (3) CN103620035B (cg-RX-API-DMAC7.html)
AU (4) AU2012249851B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013027187A2 (cg-RX-API-DMAC7.html)
CA (2) CA3165397A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013003105A1 (cg-RX-API-DMAC7.html)
CO (1) CO6821889A2 (cg-RX-API-DMAC7.html)
CY (1) CY1120304T1 (cg-RX-API-DMAC7.html)
DK (2) DK2702155T3 (cg-RX-API-DMAC7.html)
EA (1) EA025894B1 (cg-RX-API-DMAC7.html)
ES (2) ES2868950T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20170557T2 (cg-RX-API-DMAC7.html)
HU (2) HUE031595T2 (cg-RX-API-DMAC7.html)
IL (3) IL229032B (cg-RX-API-DMAC7.html)
LT (2) LT3211082T (cg-RX-API-DMAC7.html)
MX (5) MX393138B (cg-RX-API-DMAC7.html)
MY (2) MY187685A (cg-RX-API-DMAC7.html)
NZ (1) NZ717921A (cg-RX-API-DMAC7.html)
PH (1) PH12013502199A1 (cg-RX-API-DMAC7.html)
PL (2) PL2702155T3 (cg-RX-API-DMAC7.html)
PT (2) PT3211082T (cg-RX-API-DMAC7.html)
RS (1) RS61775B1 (cg-RX-API-DMAC7.html)
SG (1) SG194636A1 (cg-RX-API-DMAC7.html)
SI (2) SI3211082T1 (cg-RX-API-DMAC7.html)
TW (2) TWI698445B (cg-RX-API-DMAC7.html)
UA (1) UA115652C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012148952A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838852A2 (en) 2004-11-12 2007-10-03 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
PL2702155T3 (pl) 2011-04-25 2017-09-29 Regulus Therapeutics Inc. Związki mikroRNA i sposoby modulowania aktywności miR-21
EP2836219A1 (en) * 2012-04-10 2015-02-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for the treatment of nonalcoholic steatohepatitis
IN2014DN09134A (cg-RX-API-DMAC7.html) * 2012-04-25 2015-05-22 Regulus Therapeutics Inc
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
WO2014076196A1 (en) 2012-11-15 2014-05-22 Santaris Pharma A/S Anti apob antisense conjugate compounds
CN105378080A (zh) * 2013-05-01 2016-03-02 莱古路斯治疗法股份有限公司 用于调节mir-122的微小rna化合物和方法
WO2015061536A1 (en) * 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
US10358643B2 (en) * 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
EP3449001B1 (en) * 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
AU2018335876B2 (en) 2017-09-22 2024-03-14 University Of Washington In situ combinatorial labeling of cellular molecules
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
WO2019217369A1 (en) 2018-05-08 2019-11-14 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤
CN120505413A (zh) * 2025-07-15 2025-08-19 湖南工程学院 一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027894A2 (en) * 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
WO2009043353A2 (en) * 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
WO2009058907A2 (en) * 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009106367A1 (en) * 2008-02-27 2009-09-03 Julius Maximilians-Universität Würzburg Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes
WO2010099161A1 (en) * 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
EP2261333A2 (en) * 2006-04-03 2010-12-15 Santaris Pharma A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
WO2010144485A1 (en) * 2009-06-08 2010-12-16 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003432T2 (tr) 1998-05-22 2001-03-21 Boys Town National Research Hospital Alfa1beta1 birleştirici alıcı önleyicilerinin kullanılması ve böbrek hastalığının tedavisinde TGF-beta1 önleyicileri.
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
US7582744B2 (en) 2004-08-10 2009-09-01 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
WO2006029173A2 (en) 2004-09-08 2006-03-16 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
EP1838852A2 (en) 2004-11-12 2007-10-03 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
CN102908630B (zh) 2006-01-27 2014-11-19 Isis制药公司 6-修饰的双环核酸类似物
EP2007889A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
JP2010505427A (ja) 2006-10-09 2010-02-25 ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ）
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (en) 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
US20100261175A1 (en) 2007-06-15 2010-10-14 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
US20110257244A1 (en) 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
PL2702155T3 (pl) 2011-04-25 2017-09-29 Regulus Therapeutics Inc. Związki mikroRNA i sposoby modulowania aktywności miR-21
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
IN2014DN09134A (cg-RX-API-DMAC7.html) 2012-04-25 2015-05-22 Regulus Therapeutics Inc
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
US9725721B2 (en) 2012-09-26 2017-08-08 Mirrx Therapeutics Oligomers with improved off-target profile
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027894A2 (en) * 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
EP2261333A2 (en) * 2006-04-03 2010-12-15 Santaris Pharma A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
WO2009043353A2 (en) * 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
WO2009058907A2 (en) * 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009106367A1 (en) * 2008-02-27 2009-09-03 Julius Maximilians-Universität Würzburg Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes
WO2010099161A1 (en) * 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
WO2010144485A1 (en) * 2009-06-08 2010-12-16 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS

Also Published As

Publication number Publication date
CN103620035A (zh) 2014-03-05
EP3211082A1 (en) 2017-08-30
AU2020201403A1 (en) 2020-03-12
US20200291400A1 (en) 2020-09-17
MX393138B (es) 2025-03-24
PT3211082T (pt) 2021-04-28
MX2013012452A (es) 2014-11-21
HK1243130A1 (en) 2018-07-06
AU2012249851A1 (en) 2013-10-31
CA2833615A1 (en) 2012-11-01
EP3211082B1 (en) 2021-02-17
JP6320292B2 (ja) 2018-05-09
US12331294B2 (en) 2025-06-17
US20220098583A1 (en) 2022-03-31
ES2621863T9 (es) 2020-02-13
EP2702155B1 (en) 2017-02-01
MX2022000212A (es) 2022-04-01
AU2017219156A1 (en) 2017-09-21
CN113249381A (zh) 2021-08-13
EA201391492A1 (ru) 2014-04-30
HUE054129T2 (hu) 2021-08-30
RS61775B1 (sr) 2021-05-31
US20140107183A1 (en) 2014-04-17
TWI698445B (zh) 2020-07-11
MY175336A (en) 2020-06-19
HUE031595T2 (en) 2017-07-28
CA2833615C (en) 2022-08-30
KR20190063482A (ko) 2019-06-07
ES2621863T3 (es) 2017-07-05
IL273381A (en) 2020-05-31
KR102055172B1 (ko) 2020-01-23
PH12013502199A1 (en) 2014-01-27
TWI607016B (zh) 2017-12-01
BR112013027187A2 (pt) 2017-06-06
EP3933040A1 (en) 2022-01-05
NZ616748A (en) 2016-03-31
JP2014518619A (ja) 2014-08-07
AU2012249851A8 (en) 2013-11-14
US8912161B2 (en) 2014-12-16
NZ717921A (en) 2017-09-29
PL2702155T3 (pl) 2017-09-29
SI2702155T1 (sl) 2017-07-31
EA025894B1 (ru) 2017-02-28
CY1120304T1 (el) 2019-07-10
MX2019003090A (es) 2019-07-18
US20140329887A1 (en) 2014-11-06
HRP20210616T1 (hr) 2021-05-28
AU2012249851B2 (en) 2017-06-08
US20180155719A1 (en) 2018-06-07
US20120270928A1 (en) 2012-10-25
IL266529A (en) 2019-07-31
US9181547B2 (en) 2015-11-10
MX2022006595A (es) 2022-07-01
SG194636A1 (en) 2013-12-30
HRP20170557T2 (hr) 2020-02-21
KR20140033062A (ko) 2014-03-17
AU2022203067A1 (en) 2022-05-26
CN103620035B (zh) 2021-04-23
EP2702155B9 (en) 2020-01-01
CL2013003105A1 (es) 2014-08-01
TW201811812A (zh) 2018-04-01
LT3211082T (lt) 2021-05-10
AU2017219156B2 (en) 2020-01-02
HRP20170557T1 (hr) 2017-06-16
DK2702155T3 (en) 2017-05-01
CA3165397A1 (en) 2012-11-01
CN113151272A (zh) 2021-07-23
MX2019003089A (es) 2019-07-18
LT2702155T (lt) 2017-05-10
JP2018121646A (ja) 2018-08-09
CO6821889A2 (es) 2013-12-31
IL229032A0 (en) 2013-12-31
US20160138016A1 (en) 2016-05-19
DK3211082T3 (da) 2021-05-10
UA115652C2 (uk) 2017-12-11
SI3211082T1 (sl) 2021-08-31
PT2702155T (pt) 2017-04-03
WO2012148952A1 (en) 2012-11-01
PL3211082T3 (pl) 2021-08-02
TW201300404A (zh) 2013-01-01
US9790496B2 (en) 2017-10-17
ES2868950T3 (es) 2021-10-22
MY187685A (en) 2021-10-11
EP2702155A1 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
IL229032B (en) Microrna compounds and methods for modulating mir-21 activity
EP2714970A4 (en) Enzyme QUANTIFICATION
KR101581655B9 (ko) 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
IL270748B (en) Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors
PL2852671T3 (pl) Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna
EP2534173A4 (en) MANIPULATED COLUMN HALF-DOMAINS
EP2707510A4 (en) ISOLATION OF NUCLEIC ACIDS
BR302012001937S1 (pt) "configuração aplicada em para-lama"
EP2920319A4 (en) LOCAL ENZYMES AND METHODS OF USE
EP2753959A4 (en) PREDICTING THE POTENTIAL FOR HEAVY UNWETTERS
BR112014007029A2 (pt) métodos aperfeiçoados de terapia gênica
EP2864479A4 (en) MODULATION OF THE UBE3A ATS EXPRESSION
IL232055A0 (en) Anti-htra1 antibodies and methods of use
EP2547676A4 (en) MODULATORS OF THE HEC1 ACTIVITY AND METHOD THEREFOR
EP2776564A4 (en) MODULATION OF TMPRSS6.EXPRESSION
BR112013012319A2 (pt) inibidores de micro rna compreendendo nucleotídeos bloqueados
EP2701589A4 (en) electrode applicator
BR302012001179S1 (pt) "configuração aplicada em farol"
EP2864491A4 (en) ENZYMES AND METHODS FOR STYRENE SYNTHESIS
MA35439B1 (fr) Inhibiteurs de l'enzyme activant nedd8
EP2785714A4 (en) IMPROVED MODULATORS OF THE HEC1 ACTIVITY AND METHOD THEREFOR
EP2609107C0 (en) PROCESS FOR THE SYNTHESIS OF OLIGORIBONUCLEOTIDES
BR302012000184S1 (pt) "configuração aplicada em aparelho para laboratório"
EP2786671A4 (en) COSMETIC APPLICATION INSTRUMENT
BR302012001925S1 (pt) "configuração aplicada em calota"

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed